Sprout List Top 150! Great Bay Bio was selected as one of the 2020 Most Valuable Companies for Investment in China

Created on:2020-12-10 18:53

logo

December 10th,2020 Press Release

 

Sprout List Top 150! Great Bay Bio was selected as one of the 2020 Most Valuable Companies for Investment in China

 

[2020/12/10, Dongguan]Recently, the 2020 Venture50 finally announced the preliminary evaluation list, and Great Bay Bio was ranked among the top 150 of the Sprout List and selected as one of the most valuable companies for investment in China in 2020.

 

2020 China High Growth Enterprise CEO Summit & 15th China Top 50 Most Valuable  Enterprises for Investment

 

 

The 2020 Venture50 Awards run throughout the year, deeply digging the  potential investment opportunities in the industry, continuously releasing the entrepreneurial energy of high-growth enterprises, and capturing new rounds of opportunities in economic development. The Venture50 this year continues to explore new opportunities in entrepreneurship and  hot sectors such as healthcare, biopharmaceuticals, big consumption, education, corporate services, new energy and new materials as well as new infrastructure sectors such as electronic information, artificial intelligence, advanced manufacturing, Internet of Things, big data, and rail transportation.

 

In 2020, Venture50 has created two lists based on the differentiation of judging dimensions, namely Sprout List and Companies of the Year List, which are selected from more than 5000 companies. Great Bay Bio ranks among the top 150 list from the pre-selected 350 enterprises. Many star companies emerged from the previous Sprout List and Companies of the Year List, such as Cambricon, Kingsoft Cloud, CLOUDWALK, Galaxy Core, Megvii, Huiyihuiying, Kanghui Med, Henlius, Galactic-energy, Watrix-AI, Kuaishou, Zhihu, Himalaya,Xueqiu, Xiaohongshu, etc.

 

 

Dr. Michael Chen, CEO of Great Bay Bio, noted: "Mountains of enterprises competing for growing epitomizes the tech-empowered industrial developments in the new era.”

 

Based on artificial intelligence technology application in innovative biomedical products, Great Bay Bio has digged into the blue ocean market of AI-based biotechnology application in cell therapy, molecular diagnosis and clinical diagnosis. Relying on the power of capital, Great Bay Bio will use its technology and accelerate its commercialization to become a shepherd in the trend of the time.

 

About China's Top 50 Most Valuable Enterprises for Investment (Venture50)

 

This year marks the 14th anniversary of The "China's Top 50 Most Valuable Companies for Investment (Venture50)". As the first investment-centered enterprise selection program in China, the event was founded by Zero2IPOGroup in 2006, and it has now become the industry's authoritative reference standard for judging investment in high-growth enterprise after more than 10 years of developments. 

 

As of October 2019, more than 65,000 companies have participated in the event. The event has helped enterprises raise more than $22 billion, with a 61.2% follow-up financing rate and a listing rate of about 10% in the past three years. They have discovered and witnessed numerous outstanding ventures grow from "new shoots" to "unicorns", contributed to the successful cases of capital supporting industry implementation and feeding the real economy. This has created a thick soil for entrepreneurship and innovation in all aspects and dimensions.

 

About Great Bay Bio

 

Headquartered in Hong Kong, Great Bay Bio is a high-tech enterprise dedicated to the development of artificially intelligent biotechnology and biopharmaceutical products. Its subsidiaries, Dongguan Taili Biotech Co., Ltd. and Guangzhou Taili Biomedical Co., Ltd. have invested more than RMB 300 million in R&D equipment and have successfully established an independent and integrated technology platform for drug development and large-scale preparation.

 

The company has been honored as “Patent Fostering Enterprise”, “Patent Pilot Enterprise”, “National High-tech Enterprise”, “Dongguan City New Type R&D Institution”, and “Top Ten Foreign-funded R&D Center of Guangdong Province”, “Guangdong Provincial Gene Engineering and Pharmaceutical Engineering Research Center”, “Guangdong Provincial Doctoral Workstation”, etc. Since 2006, the company has undertaken a number of government projects and received funding from provincial and national governments for a number of projects, including the "Key Breakthrough Project in Key Areas of Guangdong and Hong Kong" and the "National Major New Drug Discovery Project".

 

 

For more details, please visit:www.greatbay-bio.com

Contact for business:info@greatbay-bio.com

Contact for media and investment: public@greatbay-bio.com

Home    News    Sprout List Top 150! Great Bay Bio was selected as one of the 2020 Most Valuable Companies for Investment in China
PV:0
Collect